Zhongxin Pharmaceutical

Zhongxin Pharmaceutical (中新药业) is a Chinese brand associated with traditional Chinese medicine (TCM), particularly 中成药 — prepared or finished Chinese medicine products. The brand operates in the consumer health and pharmaceutical space, where TCM products are commonly sold as over-the-counter remedies, prescription medicines, and health supplements. Its identity is tied to the broader TCM category, which includes herbal formulas, patent medicines, and traditional preparations used in Chinese healthcare. The brand is based in China and serves the domestic market. Its product focus aligns with the TCM segment of the pharmaceutical industry, where brands build recognition around heritage formulas, quality manufacturing, and distribution through pharmacies and hospitals. Zhongxin Pharmaceutical's website, zhongxinyao.com, serves as its official online presence. As a TCM brand, Zhongxin Pharmaceutical competes in a market shaped by both traditional practice and modern pharmaceutical regulation. The category includes well-known Chinese medicine houses and regional manufacturers, and branding often emphasizes authenticity, formulation history, and compliance with national drug standards. The brand's positioning within 中成药 places it alongside other Chinese medicine producers targeting consumers seeking traditional remedies. Details such as founding year, ownership structure, and specific flagship products are not established by the available evidence. The brand remains active and is identified primarily by its Chinese name and its association with the TCM product category.

The available evidence identifies Zhongxin Pharmaceutical (中新药业) as a traditional Chinese medicine brand associated with 中成药, or prepared Chinese medicine. The brand is linked to the TCM category, which encompasses herbal formulas and finished medicinal products used in Chinese healthcare. No founding date, ownership history, or corporate milestones are provided in the evidence. The brand's official website, zhongxinyao.com, indicates an active commercial presence. Its identity is primarily defined by its Chinese name and its focus on TCM products. Historically, TCM brands in China have developed around regional pharmaceutical manufacturing traditions, with many companies producing patent medicines and classic formulas. Zhongxin Pharmaceutical fits within this broader industry context, though specific historical details are not established by the available sources.

R&D and production of traditional Chinese patent medicines and chemical drugs

• 中成药 (prepared Chinese medicine)

  Finished traditional Chinese medicine products.

• 2019

  Fined for Selling Substandard Medicine; Suxiao Jiuxin Pill Faces Overpromotion Concerns

  Zhongxin Pharmaceutical was penalized by Tianjin regulators for selling Pu Huang that failed microscopic identification and was deemed a substandard drug. Its major product Suxiao Jiuxin Pill was questioned over exaggerated promotion, and in 2021 the National Medical Products Administration required label revisions to add contraindications and adverse reactions. Illegal gains were confiscated and the label was revised.

  Source

Read more

• 2020.04.19

  Reported2020.04.19

  Zhongxin Pharmaceutical reports 2019 results[3]中新药业发布2019年业绩finance.sina.com.cn

  Zhongxin Pharmaceutical released its 2019 annual report, reporting revenue of 6.994 billion yuan, up 9.99% year over year, and net profit of 626 million yuan, up 11.37%.

Read more

1. 1Fined for Selling Substandard Medicine; Suxiao Jiuxin Pill Faces Overpromotion Concernsfinance.ce.cn
2. 2Fined for Selling Substandard Medicine; Suxiao Jiuxin Pill Faces Overpromotion Concernsm.jiemian.com
3. 3中新药业发布2019年业绩finance.sina.com.cn